Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

Company Overview - Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on pioneering medicines that transform patients' lives, with a unique genomics target discovery platform called Genome5000™ [4][5] - The company has commercially launched one medicine, INPEFA® (sotagliflozin), in the United States and has a pipeline of promising drug candidates in various stages of development for neuropathic pain, diabetes, metabolism, and other indications [5][6] Research Presentations - Lexicon will present three poster presentations at the 84th Scientific Sessions of the American Diabetes Association from June 21 - 24, 2024, in Orlando, Florida [4] - The presentations include topics such as the burden of diabetic peripheral neuropathic pain and the impact of sotagliflozin as an add-on treatment for inadequately controlled type 2 diabetes [5] Drug Development - LX9211 is an investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1), identified as a promising treatment for neuropathic pain, with preclinical studies showing effectiveness without affecting opiate pathways [6] - Sotagliflozin is an oral inhibitor of SGLT2 and SGLT1 proteins, studied in clinical trials involving approximately 20,000 patients across various conditions including heart failure and chronic kidney disease [7]